论文部分内容阅读
对16例由骨髓增生异常综合征转化成的急性白血病给予联合方案化疗。同时以16例病前无骨髓增生异常综合征病史的急性白血病为对照。转白组CR5例,CR率为31.3%,对照组CR12例,CR率为75%,二组比较有显著差异性(P<0.05),在化疗后下一疗程化疗前转白组的白细胞恢复低于3×109/L有8例,对照组2例,二组比较有显著差异(P<0.05)。生存曲线显示对照组的生存率高于转白组(P<0.05)。
16 cases of myelodysplastic syndromes into acute leukemia given chemotherapy. At the same time, 16 cases of acute leukemia with no history of myelodysplastic syndrome were used as control. CR5 in CRP was 31.3% in CRP group and CR12 in CRP group, the CR rate was 75% in CRP group (P <0.05) Group of white blood cell recovery less than 3 × 109 / L in 8 cases, control group 2 cases, the two groups were significantly different (P <0.05). Survival curves showed that the survival rate of the control group was higher than that of the transfection group (P <0.05).